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Background: The best investigational drug to treat cystic ﬁbrosis (CF) patients with themost common CF-causing
mutation (F508del) is VX-809 (lumacaftor) which recently succeeded in Phase III clinical trial in combination
with ivacaftor. This corrector rescues F508del-CFTR from its abnormal intracellular localization to the cell surface,
a trafﬁc defect shared by all Class II CFTRmutants. Our goal here is to test the efﬁcacy of lumacaftor in other Class
II mutants in primary human bronchial epithelial (HBE) cells derived from CF patients.
Methods: The effect of lumacaftor was investigated in primary HBE cells from non-CF and CF patients with
F508del/F508del, A561E/A561E, N1303K/G542X, F508del/G542X and F508del/Y1092X genotypes by measure-
ments of Forskolin plus Genistein-inducible equivalent short-circuit current (Ieq-SC-Fsk + Gen) in perfused open-
circuit Ussing chambers. Efﬁcacy of corrector C18 was also assessed on A561E/A561E and F508del/F508del cells.
Results: Our data indicate that A561E (when present in both alleles) responds positively to lumacaftor treatment
at equivalent efﬁcacy of F508del in primary HBE cells. Similarly, lumacaftor has a positive impact on Y1092X, but
not on N1303K. Our data also show that cells with only one copy of F508del-CFTR respond less to VX-809. More-
over, there is great variability in lumacaftor responses among F508del-homozygous cells from different donors.
Compound C18 failed to rescue A561E-CFTR but not in F508del-CFTR, thus plausibly it has a differentmechanism
of action distinct from lumacaftor.
Conclusions: CF patients with A561E (and likely also those with Y1029X) can potentially beneﬁt from lumacaftor.
Moreover, themethodology used here exempliﬁes how ex vivo approaches may apply personalized therapies to
CF and possibly other respiratory diseases.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Cystic ﬁbrosis (CF), the most common life-shortening genetic dis-
ease affecting approximately 80,000 people worldwide (Bobadilla
et al., 2002; The Molecular Genetic Epidemiology; Farrell, 2008;
Rodrigues et al., 2009), is caused by mutations in the gene encoding
the cystic ﬁbrosis transmembrane conductance regulator (CFTR) pro-
tein. The dominating clinical CF phenotype is the respiratory disease,
being hallmarks of this disease the very thickmucus obstructing the air-
ways, chronic inﬂammation and persistent infectionsmostly by Pseudo-
monas aeruginosa, which altogether lead to eventual impairment ofansmembraneconductance reg-
C, epithelial Na+ channel; Fsk,
epithelial cells; SEM, standard
ce; Vte, transepithelial voltage;
. This is an open access article underrespiratory function (Bell et al., 2015). Other CF symptoms include pan-
creatic dysfunction, elevated sweat electrolytes andmale infertility, but
the progressive loss of lung function remains the leading cause of mor-
bidity and mortality (Bell et al., 2015).
Most current treatments for CF target the secondary effects of dys-
function of CF lung disease to alleviate its symptoms (mucolytics, anti-
biotics, etc). However, new therapies modulating defective CFTR, the
basic defect underlying CF, have started to hit the clinic and several
others are in trial or in development.
CFTR is an essential epithelial anion channel that regulates several
other channels and transporters, altogether regulating ion homeostasis
and water content of epithelia surfaces. This member of the ABC trans-
porter family has been reported to host N1900 mutations, presumed to
be CF-causing, albeit some still of unknown impact (Sosnay et al., 2013).
Such genetic diversity makes the drug discovery based on protein res-
cue a huge task. Therefore, CFTRmutations are grouped into 6 function-
al classes, so as to apply the same CFTR-corrective therapy within each
functional class to drastically downscale the drug discovery pipelinethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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standing, one single mutation — F508del, occurring in ~85% of CF pa-
tients in at least one allele and associated with severe CF —remains
the most common CF mutation worldwide. F508del-CFTR is associated
with defective trafﬁc (Class II) which precludes it from reaching the
cell surface [reviewed in (Amaral, 2004)].
Themost attractive CFTR-modulator therapies involve: correctors to
rescue F508del-CFTR to the cell surface and potentiators to restore CFTR
mutants which exhibit a channel regulation defect (Class III). Potentia-
tor ivacaftor, the ﬁrst CFTR-targeting drug, was recently approved by
FDA/EMA, albeit for a rare mutation — G551D (Ramsey et al., 2011)
and for other Class III CFTR mutations (Van Goor et al., 2014; De Boeck
et al., 2013), which, altogether only target ~5% of CF patientsworldwide.
For CF patients with themost frequent mutation F508del, the best
investigational drug is VX-809 (or lumacaftor, Vertex), reported to
rescue ~25% CFTR activity in F508del/F508del primary human bron-
chial (HBE) cells (Van Goor et al., 2011). Very recently, this investi-
gational drug, in combination with ivacaftor, succeeded in showing
signiﬁcant efﬁcacy in a Phase III clinical trial on F508del/F508del pa-
tients (Prease release), an achievement that will likely result in its
FDA-approval. lumacaftor, plausibly acting by correcting the folding
of a critical contact site in CFTR structure (Farinha et al., 2013),
rescues the abnormal intracellular localization of F508del-CFTR to
the cell surface, a trafﬁc defect that is common to all Class II CFTR
mutants.
Our aim herewas to assess efﬁcacy of lumacaftor on other CFTRmu-
tants with the same trafﬁc defect as F508del (Class II (Amaral and
Farinha, 2013)). Mutations tested here include: A561E, quite frequent
in Southern-European and South-American countries like in Portugal
(Mendes et al., 2003), Spain (Moya-Quiles et al., 2009) and Brazil
(Servidoni et al., 2013) and N1303K, linked to ancient Mediterranean
populations (Bobadilla et al., 2002). In addition we tested VX-809 in
HBE cells bearing 2 nonsense mutations: G542X and Y1092X, both in
heterozygosity with F508del.
Our data in primaryHBE cells show that lumacaftor rescues A561E at
equivalent efﬁcacy of F508del, but N1303K is not signiﬁcantly rescued.
Data also show that VX-809 rescues F508del in cells from different do-
nors with great variability. Compound C18 (lumacaftor analogue, also
reported to rescue F508del) failed to rescue A561E-CFTR, thus plausibly
rescuing CFTR by a different mechanism of action than lumacaftor.
We conclude that CF patients with the A561E mutation can poten-
tially beneﬁt from lumacaftor and personalized medicine is the way
forward to tackle CF.2. Methods
2.1. Culture Conditions of Primary Human Bronchial Epithelial Cells
Human lung tissues fromCF donorswith the F508del/F508del (2 do-
nors), A561E/A561E, N1303K/G542X, F508del/G542X and F508del/
Y1092X genotypes, were obtained from the Cardio-Thoracic Surgery
Department (University Hospital la Fe, Valencia, Spain) after receiving
patient's written consent and approval by the hospital Ethics Commit-
tee. Primary cultures of humanbronchial epithelial (HBE) cellswere iso-
lated as described previously (Fulcher and Randell, 2013) and then
expanded and grown on collagen IV-coated porous membranes
(Snapwell, Corning-Costar®, Tewksbury, MA, USA) also as described
(Moniz et al., 2013). Transepithelial electrical resistance (TEER) of theFig. 1. Effect of lumacaftor (VX-809) on cAMP-induced Isc-eq in primary cultures of HBE cells fr
showing transepithelial voltagemeasurements (Vte) obtained for CF primary airway HBEmonol
F508del/F508del-donor 2 (e, f); and A561E/A561E (g, h). Cellswere preincubated for 24 hwith e
Amiloride (20 μM)was kept during the whole experiment duration to avoid interference of EN
following the application of luminal forskolin alone (Fsk, 2 μM)orwith genistein (Gen, 25 μM). T
values in Table S1).HBE monolayers growing on porous membranes was measured with
the chopstick electrode (STX2 from WPI®, Berlin, Germany) and elec-
trophysiological analyses were carried out in monolayers with resis-
tance values above 600 Ω·cm2. No signiﬁcant differences were
measured for HBE monolayers with the different genotypes (Fig. S1).
HBE cells were incubated with 3 μM VX-809 (lumacaftor), 5 μM C18,
or DMSO vehicle alone (0.1%, v/v) for 24 h prior to the experiments as
a control.2.2. Micro-Ussing Chamber Recordings
Monolayers of HBE cells were mounted in micro-Ussing chambers
and analysed under open-circuit conditions at 37 °C, as before (Moniz
et al., 2013). Values for the transepithelial voltage Vte were referenced
to the basal surface of the epithelium. Transepithelial resistance Rte was
determined by applying 1 s current pulses of 0.5 μA (5 s-period). The
cAMP-stimulated CFTR equivalent short-circuit currents (Ieq-sc)were cal-
culated according to Ohm's law from Vte and Rte (Ieq-sc = Vte / Rte), with
appropriate correction for ﬂuid resistance. Ringer solution Cl− concen-
trations apical and basal were 30 mM and 145 mM respectively and pH
adjusted to 7.4. Following a 20-min equilibrium period, amiloride
(20 μM) added to the luminal side to block epithelial Na+ channel
(ENaC)-mediated Na+ ﬂux, then cAMP agonist, 2 μM forskolin (Fsk),
the CFTR potentiator 25 μM genistein (Gen), and the CFTR channel
blocker CFTR Inh172 (30 μM) were added sequentially.2.3. Statistical Analysis
Statistical comparisons were made using two-tailed Student's t tests
and statistically signiﬁcance was considered for p ≤ 0.05.3. Results
3.1. Response to lumacaftor for Class II Mutants Assessed by CFTR-Mediated
Chloride Secretion
The effects of 24 h-treatment with lumacaftor were assessed here
by determining CFTR-mediated Cl− secretion in HBE cells from CF
donors with the following genotypes (Fig. 1): wt/wt control (a, b);
F508del/F508del-Donor 1 (c, d); F508del/F508del-Donor 2 (e, f);
A561E/A561E (Fig. 1g, h) and also on the additional genotypes
(Fig. 2): N1303K/G542X (a, b), F508del/G542X (c, d); F508del/
Y1092X (e, f). Since G542X is a “null” variant (i.e., generating no pro-
tein) results on the latter are representative of the N1303K variant,
albeit in a single dose. The equivalent short-circuit current (Ieq-SC)
as a measurement of CFTR-mediated Cl− secretion (see Methods)
was determined for cAMP-stimulation by both Forskolin (Ieq-SC-Fsk)
alone or with Genistein (Ieq-SC-Fsk + Gen).
These results show that Fsk + Gen responses of F508del/F508del (2
donors), A561E/A561E F508del/G542X and F508del/Y1092X cells after
VX-809/lumacaftor treatment were signiﬁcantly different from those
under DMSO, while that of N1303K/G542X cells was not signiﬁcantly
different (Fig. 3b).
The respective Fsk responses after VX-809 (Fig. 3a) were lower that
the corresponding Fsk+Gen responses, as expected due to the absence
of the potentiator, but differences between VX-809 and DMSO-treated
cells were similarly signiﬁcant.om CF patients with class II mutations. Original Ussing chamber (open-circuit) recordings
ayerswith different CFTR genotypes: wt/wt control (a, b); F508del/F508del-donor 1 (c, d);
ither 3 μM/24h lumacaftor/VX-809 (b, d, f, h) or DMSO (0.1%v/v) vehicle control (a, c, e, g).
aC-mediated Na+ currents. Negative transepithelial voltage (Vte) deﬂections are observed
he latter are fully reverted by application of 30 μM Inh172, a speciﬁc CFTR inhibitor (see also
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equivalent short-circuit currents in response to Forskolin plus Genistein
(Ieq-sc-Fsk + Gen) after VX-809 vs DMSO (Table S2) and as percentage of
rescue vs non-CF cells (Fig. 3c, Table S2). These data again clearly
show a positive effect of VX-809 on HBE cells with genotypes F508del/
F508del (both donors), A561E/A561E, F508del/G542X and F508del/Fig. 2. Effect of lumacaftor (VX-809) on cAMP-induced Isc-eq in primary cultures of HBE cells fr
cordings showing transepithelial voltagemeasurements (Vte) obtained for CF primary airwayH
F508del/Y1092X (e, f). Cellswere pre-incubated for 24hwith either 3 μM/24h lumacaftor/VX-8
legend (see also values in Table S1).Y1092X but not on N1303K/G542X cells. Of note is the striking differ-
ence between the responses of the two F508del/F508del donors.
It is also interesting to note the difference in responses by
the F508del/G542X and F508del/Y1092X cells. Since F508del/
Y1092X cells (but not F508del/G542X cells) already exhibit
levels of Ieq-sc-Fsk or Ieq-sc-Fsk + Gen before VX-809, we assessedom CF patients with different CFTR mutations. Original Ussing chamber (open-circuit) re-
BEmonolayerswith different genotypes: N1303K/G542X (a, b); F508del/G542X (c, d); and
09 (b, d, f) orDMSO(0.1%v/v) vehicle control (a, c, e). Other conditions as described in Fig. 1
Fig. 3. Summary of the effect of lumacaftor (VX-809) on HBE cells from CF patients with different genotypes. Graphs represent values of Ieq-sc (μA/cm2) calculated from voltage deﬂection
obtained for the responses to Fsk (a) or toGen+Fsk (b), after 24 h treatmentwith 0.1%DMSO(white bars) or 3 μMVX-809 (black bars) for HBE cellswith different genotypes, as indicated
below the graphs. (c) Percentage of Ieq-sc rescue in response to Forskolin plus Genistein (Ieq-sc-Fsk + Gen) after VX-809 vs DMSO vs non-CF cells (see also Table S2). *indicates statistically
signiﬁcant (p N 0.05) and “ns” not signiﬁcant.
151N.T. Awatade et al. / EBioMedicine 2 (2015) 147–153the levels of the non-F508del transcripts in these two cells, i.e., those
with the stop mutation to determine the respective levels of
nonsense-mediated mRNA decay (Table S3). Data, show that the levelsFig. 4.Original tracings and summary of the effect of C18 in A561E/A561E and F508del/F508de
tained for the analysis of CF primary airway HBE monolayers with A561E/A561E and F508del/
values obtained for responses to Fsk (white bars) or Fsk + Gen (black bars) after 24 h-treatme
tistically signiﬁcant (p N 0.05).of Y1092X-transcripts are higher than those from G542X (Table S3), in-
dicating that Y1092X transcripts are less prone to degradation through
nonsense-mediated decay.l primary HBE cells. (a, b) represent original Ussing chamber (open-circuit) recordings ob-
F508del treated with 5 μM C18 for 24 h. (c) Graph represents summary of Isc-eq (μA/cm2)
nt with DMSO, VX-809/lumacaftor or C18 as indicated (see also Table S4). * indicates sta-
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A561E/A561E HBE cells were also treated with C18 compound,
described as a lumacaftor analogue (Eckford et al., 2014). As demon-
strated by the original tracing in Fig. 4a, the responses elicited by either
Fsk or Fsk + Gen in A561E/A561E cells pre-incubated with C18 are
lower than those in F508del/F508del cells (Fig. 4b) and this difference
is statistically different (Fig. 4c). Moreover, the response of A561E/
A561E cells after C18 treatment is also signiﬁcantly lower than that in
lumacaftor-treated cells, while those of F508del/F508del cells after
C18 and VX-809 are similar (Fig. 1c, Table S4). Indeed, the Fold rescue
of Ieq-sc-Fsk + Gen in A561E/A561E cells after C18 treatment was 1.93×,
while this value was 6.51× F508del/F508del cells. Similarly, the per-
centages of rescue by C18 vs non-CF cells (wt/wt) were ~0.8% and
~5.0% for A561E/A561E F508del/F508del cells, respectively.
These data also indicate that the response of A561/A561E HBE cells
to C18 is lower than to lumacaftor, when these cells are stimulated by
Gen, but interestingly, not when stimulated only by Fsk. To conﬁrm
these data, Western blot was performed in BHK cells stably expressing
F508del or A561E mutant protein. Data show that VX-809 rescues
both F508del and A561E-CFTR, while C18 failed to rescue A561E-CFTR
but not in F508del-CFTR protein (Fig. S2). These data are thus consistent
with those obtained for A561E/A561E cells treated with C18.
4. Discussion
CF has been for a long time a paradigmaticmonogenic disease for the
advancement of both biomedical science and clinical practice. CF also pi-
oneers drug discovery programmes for rare diseases, as recently dem-
onstrated by the recent approval for the clinic of ivacaftor, a
compound that treats the basic gating defect associated with Class III
CFTR protein mutants.
However, this novel treatment only applies to 9 of the 1900 CFTR
gene mutations reported to date (~5% of all CF patients). The CF com-
munity should thus work fast to determinewhether ivacaftor, or the in-
vestigational drug lumacaftor (for Class II mutants) rescue other CFTR
mutants and thus can be extended to more CF patients.
The objective of this study was to evaluate the effect of lumacaftor
on additional CFTRmutants which, similarly to themost frequentmuta-
tion F508del (Van Goor et al., 2011), also affect the trafﬁc of the protein
to the plasma membrane. To this end, we used the best known in vitro
CF model of human airways, consisting in primary cultures of human
bronchial epithelial cells (HBE) grown as monolayers in porous ﬁlters
and we used then for CFTR bioelectric measurements in perfused
micro-Ussing chambers (Moniz et al., 2013).
Our data show that the effect of lumacaftor on A561E/A561E HBE
cells was equivalent to that of this investigational drug in F508del/
F508del cells. Indeed, after the incubation of A561E/A561E cells with
3 μM lumacaftor for 24 h, responses obtained in the Ussing chamber
were 7-fold higher than when cells were incubated with DMSO-
vehicle, representing ~6% of rescue vs non-CF cells. For F508del/
F508del cells responses of lumacaftor-treated cells were 8/14-fold
higher than those under DMSO, representing 5–15% of rescue vs non-
CF cells. These data seem to indicate that the previously characterized
trafﬁcking defect of the A561E-CFTR protein (Mendes et al., 2003) can
be, as least partially, corrected by lumacaftor. Interestingly, a previous
study showed that A561E-CFTR can be rescued to the cell surface by
the same genetic revertants as F508del-CFTR (Roxo-Rosa et al., 2006).
In another more recent study, the A561E-CFTR channel was also de-
scribed to have similar mechanisms of dysfunction and response to po-
tentiators as F508del-CFTR (Wang et al., 2014). Of note is the striking
difference between the responses of the two F508del/F508del donors,
which can potentially be a predictor of variable patients' response to
this investigational drug. Data presented here also show a positive effect
of VX-809 onHBE cells with genotypes F508del/G542X (~4% vs non-CF)
and F508del/Y1092X (~7% vs non-CF) but not on N1303K/G542X cells.Our data also lead to the conclusion that the A561E responses to
lumacaftor and its analogue C18 do not totally overlap, as observed
from the signiﬁcantly lower Fsk + Gen response of A561E/A561E cells
pre-incubated with C18 vs those under lumacaftor. In contrast,
F508del-CFTR responds similarly to both correctors, similarly to what
was previously reported (Eckford et al., 2014). Noticeably, however,
the Fsk-response of C18-treated A561E/A561E cells is signiﬁcantly
higher than in the DMSO-treated cells (Fig. 4c). Therefore, the failure
in C18-treated to signiﬁcant respond to the further stimulation by po-
tentiator Genistein, might be due to a possible dual activity (corrector
and potentiator) of the C18 compound as suggested (Eckford et al.,
2014),which likelywould be overlappingwith that of Gen.Nonetheless,
C18 also failed to rescue A561E-CFTR as assessed byWestern blot, while
VX-809 induces a detectable levels of mature A561E-CFTR (Fig. S2). Al-
though those authors have used a higher C18 concentration for a longer
pre-incubation time (6 μM/48 h) (Eckford et al., 2014), the conditions
we employed here (5 μM/24 h) were also used in another study
(Holleran et al., 2012) and in fact correspond to the concentration
range recommended by CFFT (3–6 μM).
In contrast to the effect on A561E/A561E HBE cells, themagnitude
of the response of lumacaftor-treated N1303K/G542X cells was just
slightly higher by ~2-fold (both under Fsk and Gen) and not statisti-
cally different from that in DMSO-treated cells. Moreover, the per-
centage of rescue vs non-CF cells was barely 0.5%, thus showing a
lack of an effect by VX-809 on N1303K. Two hypotheses may account
for this lack of a signiﬁcant response. Firstly, N1303K located in the
second nucleotide binding domain (NBD2) of CFTR protein, may
cause a different structural defect from that of F508del or A561E,
both located in NBD1. Indeed, recent studies have suggested that
the putative binding site of VX-809/lumacaftor is a “structural pock-
et” between NBD1 and the fourth intracellular loop (ICL4) of the sec-
ond transmembrane domain (Farinha et al., 2013; He et al., 2013).
Plausibly, NBD2-located N1303K creates a distinct defect which un-
likely would be corrected by the lumacaftor. Secondly, it is possible
that the response of a single copy of N1303K (the other CFTR allele
is G542X, a “null” variant) may be insufﬁcient to observe an effect
similar in magnitude to that of A561E/A561E or F508del/F508del
cells. Contradicting the latter hypothesis are the positive responses
of the F508del/G542X and F508del/Y1092X cells, showing that VX-
809 can elicit a detectable effect on a single dose of F508del, in con-
trast to N1303K.
Interestingly, the response of F508del/Y1092X cells is almost double
to that of F508del/G542X. While difference could be due to intrinsic re-
sponses of the F508del alleles from each of these donors, it is also plau-
sible that the Y1092X mutation, given its localization towards the C-
terminus of the protein, does not totally abolish the production of func-
tional CFTR protein, in contrast to G542X. Indeed, these HBE cells al-
ready exhibit levels of Ieq-sc-Fsk or Ieq-sc-Fsk + Gen before VX-809, which
are higher than those of F508del/F508del cells, suggesting that
Y1092X-CFTR protein may elicit such response. Moreover, the levels of
Y1092X-transcripts (Table S3) are higher than those from G542X,
again indicating that Y1092X transcripts are less prone to degradation
through nonsense-mediated decay. It is thus likely that Y1092X origi-
nates CFTR protein with residual function with some positive response
to VX-809.
In conclusion, our data suggest that CF patients bearing the A561E
mutation, which is associated with a severe clinical phenotype and
quite common in some countries (Mendes et al., 2003), can potentially
beneﬁt from lumacaftor treatment. Similarly, lumacaftor seems to have
a positive impact onY1092X. Our data also show that cellswith only one
copy of F508del-CFTR respond less to VX-809. Moreover, there is great
variability in lumacaftor responses among F508del-homozygous cells
from different donors. Importantly, the methodology used in this
study exempliﬁes how ex vivo approaches may apply personalized
therapies to Cystic Fibrosis and possibly other respiratory diseases.
These data actually demonstrates the main topic of this study which is
153N.T. Awatade et al. / EBioMedicine 2 (2015) 147–153each patient should be tested individually for the responsiveness to the
compounds.
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